247 related articles for article (PubMed ID: 33830701)
21. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
Yu J; Tostanoski LH; Peter L; Mercado NB; McMahan K; Mahrokhian SH; Nkolola JP; Liu J; Li Z; Chandrashekar A; Martinez DR; Loos C; Atyeo C; Fischinger S; Burke JS; Slein MD; Chen Y; Zuiani A; Lelis FJN; Travers M; Habibi S; Pessaint L; Van Ry A; Blade K; Brown R; Cook A; Finneyfrock B; Dodson A; Teow E; Velasco J; Zahn R; Wegmann F; Bondzie EA; Dagotto G; Gebre MS; He X; Jacob-Dolan C; Kirilova M; Kordana N; Lin Z; Maxfield LF; Nampanya F; Nityanandam R; Ventura JD; Wan H; Cai Y; Chen B; Schmidt AG; Wesemann DR; Baric RS; Alter G; Andersen H; Lewis MG; Barouch DH
Science; 2020 Aug; 369(6505):806-811. PubMed ID: 32434945
[TBL] [Abstract][Full Text] [Related]
22. Recommendations were made for diagnosis and management of allergic reactions to COVID-19 vaccines.
Maki DG
Ann Intern Med; 2021 Nov; 174(11):JC122. PubMed ID: 34724408
[TBL] [Abstract][Full Text] [Related]
23. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.
Ma C; Su S; Wang J; Wei L; Du L; Jiang S
Microbes Infect; 2020; 22(6-7):245-253. PubMed ID: 32437926
[TBL] [Abstract][Full Text] [Related]
24. Targets and strategies for vaccine development against SARS-CoV-2.
Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
[TBL] [Abstract][Full Text] [Related]
25. [Not Available].
Klimek L; Chaker AM; Cuevas M
Laryngorhinootologie; 2021 May; 100(5):344-354. PubMed ID: 33684947
[TBL] [Abstract][Full Text] [Related]
26. [Vaccines against COVID-19].
Fathi A; Mellinghoff SC
Internist (Berl); 2021 Nov; 62(11):1191-1201. PubMed ID: 34613428
[TBL] [Abstract][Full Text] [Related]
27. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
28. Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination.
Kreps S; Prasad S; Brownstein JS; Hswen Y; Garibaldi BT; Zhang B; Kriner DL
JAMA Netw Open; 2020 Oct; 3(10):e2025594. PubMed ID: 33079199
[TBL] [Abstract][Full Text] [Related]
29. Vaccine nationalism: a predicament in ending the COVID-19 pandemic.
Lagman JDN
J Public Health (Oxf); 2021 Jun; 43(2):e375-e376. PubMed ID: 33730161
[TBL] [Abstract][Full Text] [Related]
30. COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.
Ong E; Wong MU; Huffman A; He Y
Front Immunol; 2020; 11():1581. PubMed ID: 32719684
[TBL] [Abstract][Full Text] [Related]
31. Prospects of COVID-19 Vaccination in Romania: Challenges and Potential Solutions.
Dascalu S; Geambasu O; Covaciu O; Chereches RM; Diaconu G; Dumitra GG; Gheorghita V; Popovici ED
Front Public Health; 2021; 9():644538. PubMed ID: 33643998
[TBL] [Abstract][Full Text] [Related]
32. Insights from American College of Allergy, Asthma, and Immunology COVID-19 Vaccine Task Force: Allergic Reactions to mRNA SARS-CoV-2 Vaccines.
Murphy KR; Patel NC; Ein D; Hudelson M; Kodoth S; Marshall GD; Parikh P; Blaiss MS
Ann Allergy Asthma Immunol; 2021 Apr; 126(4):319-320. PubMed ID: 33493641
[No Abstract] [Full Text] [Related]
33. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
Sharma O; Sultan AA; Ding H; Triggle CR
Front Immunol; 2020; 11():585354. PubMed ID: 33163000
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X
Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281
[TBL] [Abstract][Full Text] [Related]
35. Determining the frequency of serious adverse reactions of inactive SARS-COV-2 vaccine.
Kaya F; Pirincci E
Work; 2021; 69(3):735-739. PubMed ID: 34219684
[TBL] [Abstract][Full Text] [Related]
36. Is there a role for childhood vaccination against COVID-19?
Eberhardt CS; Siegrist CA
Pediatr Allergy Immunol; 2021 Jan; 32(1):9-16. PubMed ID: 33113210
[TBL] [Abstract][Full Text] [Related]
37. Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns.
Zellweger RM; Wartel TA; Marks F; Song M; Kim JH
Expert Rev Vaccines; 2020 Aug; 19(8):691-698. PubMed ID: 32838605
[TBL] [Abstract][Full Text] [Related]
38. Editorial: Vaccination during the COVID-19 pandemic.
Danchin M
Aust J Gen Pract; 2020 Oct; 49(10):621. PubMed ID: 33015675
[No Abstract] [Full Text] [Related]
39. COVID-19 Vaccine in Children: Where Do We Stand?
Kumar J; Meena J
Indian Pediatr; 2021 Feb; 58(2):194-195. PubMed ID: 33632966
[No Abstract] [Full Text] [Related]
40. Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection.
Simon HU; Karaulov AV; Bachmann MF
Int Arch Allergy Immunol; 2020; 181(8):624-628. PubMed ID: 32544911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
